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ABSTRACT
Background. Not all patients respond equally to neoadju-
vant chemoradiotherapy (nCRT), with subsequent effects on
survival. The systemic inflammatory response has been
shown to predict long-term outcomes in colorectal cancer.
The current study examined the association between sys-
temic inflammation and nCRT in patients with rectal cancer.
Methods. Between 1999 and 2010, patients who under-
went nCRT were identified. Serum measurements of
hemoglobin, C-reactive protein, albumin, modified Glas-
gow prognostic score (mGPS), and differential white cell
counts were obtained before and after nCRT. The Ro¨del
scoring system measured pathologic tumor regression, and
magnetic resonance imaging and computed tomography
determined radiologic staging.
Results. The study included 79 patients. Of these patients,
37% were radiologically downstaged, and 44% were cat-
egorized as showing a good pathologic response (Ro¨del
scores 3 and 4). As a validated measure of the systemic
inflammatory response, mGPS (P = 0.022) was associated
with a poor pathologic response to nCRT. A radiologic
response was associated with a good pathologic response to
treatment (P = 0.003). A binary logistic regression model
identified mGPS (odds ratio [OR] 0.27; 95% confidence
interval [CI] 0.07–0.96; P = 0.043) and radiologic
response (OR 0.43; 95% CI 0.18–0.99; P = 0.048) as
strong independent predictors of a pathologic response to
treatment.
Conclusion. The current study showed that a systemic
inflammatory response before nCRT is associated with a
poor pathologic response. Further study in a prospective
controlled trial setting is warranted.
Colorectal cancer (CRC) is the third most common
cancer and the second highest cause of cancer death in the
United Kingdom.1 The 5-year survival rate for CRC still is
less than 60% with surgery alone, offering the only chance
of cure.
Rectal cancers comprise about one third of surgical
resections for colorectal cancer.2 The widely adapted sur-
gical technique of total mesorectal excision (TME),
increased centralization, specialization of rectal surgery,
and earlier disease detection have led to improved survival
in the last 30 years.3,4 Preoperative neoadjuvant radio-
therapy with or without chemotherapy currently is accepted
as a standard of care for patients with margin-threatening
rectal cancer. This increases disease-free survival (DFS)
and sphincter preservation rates and improves circumfer-
ential resection margins and local recurrence rates.5–8
Current management of CRC in the United Kingdom
involves evaluating patients using magnetic resonance
imaging (MRI) and computed tomography (CT) before
treatment to identify those with margin-threatening disease
(T3 or T4).9 These patients are offered neoadjuvant
chemoradiotherapy (nCRT) before surgical resection.10
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Not all patients respond to nCRT, and there is a need to
identify biomarkers of response because treatment is
associated with significant morbidity. Ro¨del et al.11 have
shown that the presence of spontaneous apoptosis in the
resected specimen is a good marker of tumor regression
and improved prognosis.
The prognostic value of the systemic inflammatory
response (SIR) has been widely studied in gastrointestinal
cancers, particularly in the operative setting, using mea-
surements of circulating markers including C-reactive
protein (CRP), albumin, the modified Glasgow prognostic
score (mGPS), the neutrophil lympocyte ratio (NLR), the
platelet-to-lymphocyte ratio (PLR), and more recently, the
neutrophil-platelet score (NPS) and the derived neutrophil-
to-lymphocyte ratio (dNLR).12–16
This study investigated the association between markers
of the systemic inflammatory response and the pathologic
response to nCRT in patients with rectal cancer.
METHODS
Patients who underwent nCRT and surgical resection for
rectal adenocarcinoma between 1999 and 2010 were
identified from a prospectively maintained colorectal
cancer database. Patients with biopsy-confirmed adeno-
carcinoma of the rectum who received long-course nCRT
and attempted curative resection were included in the
study. Patients with margin-threatening disease and radio-
logic evidence of locally involved lymph nodes underwent
nCRT as decided by the local colorectal cancer multidis-
ciplinary teams. Patients were excluded from the study if
they were considered unsuitable for long-course therapy,
had undergone previous surgery for rectal cancer, or had
documented chronic inflammatory conditions.
The patients were assessed and diagnosed according to
standard national guidelines. Those with biopsy-confirmed
rectal adenocarcinoma underwent staging CT and MRI to
assess local extent of disease and evidence of metastases.
These were repeated at the clinician’s request after nCRT
for all the patients.
The nCRT regimen was at the discretion of the treating
oncologists. Radiotherapy was delivered at a standard dose
of 45 Gy in 25 fractions, with a range of 39.6–50 Gy. The
concurrent chemotherapy regimens used included 5-fluo-
rouracil (5-FU), capecitabine, or combinations of these
with oxaliplatin and mitomycin.
CLINICOPATHOLOGIC CHARACTERISTICS
This study was approved by the West of Scotland
Research Ethics Committee, Glasgow. Pathologic speci-
mens were processed and reported by specialist
gastrointestinal cancer pathologists, and final staging was
reported as per the International Union Against Cancer
(UICC) tumor-node-metastasis (TNM) staging system.
This included a description of the lymph node ratio, the
total lymph nodes retrieved, and tumor differentiation.
Resection margin status was described as either free of
tumor (R0), microscopically involved (R1), or macro-
scopically involved (R2).
Pretreatment blood test measurements were defined as
the sample taken closest to the nCRT start date and
included hemoglobin (Hb), neutrophil, lymphocyte and
platelet counts, carcinoembryonic antigen (CEA), albumin,
and CRP. Anemia was defined as levels lower than 13 g/dL
(men) and lower than 11.5 g/dL (women). The CRP level
was considered high if it exceeded 10 mg/L, and hypoal-
buminemia was defined as a level lower than 35 g/L.
The mGPS was calculated as previously described.1
Briefly, patients with an elevated CRP were assigned an
mGPS score of 1 or 2 depending on the presence or
absence of hypoalbuminaemia. The NLR and PLR were
calculated as standard, with cutoffs of 5 or lower (NLR)
and 300 or lower (PLR) considered normal. The NPS was
calculated as recently described.15 Patients with a neu-
trophil count lower than 7.5 9 109/L and a platelet count
lower than 400 9 109/L scored 0. Those with either a
neutrophil count higher than 7.5 9 109/L or a platelet
count higher than 400 9 109/L scored 1, and those with
both a neutrophil count higher than 7.5 9 109/L and a
platelet count higher than 400 9 109/L scored 2. This
measurement (the derived neutrophil-Lymphocyte ratio or
dNLR) is calculated by the neutrophil count divided by the
(white cell count minus the neutrophil count).16 The CEA
was deemed normal at a value lower than 5 lg/L.
Assessment of Response to nCRT
Radiologic response to therapy was defined as tumor
downstaging according to pre- and postneoadjuvant treat-
ment imaging. The MRI and CT images were reported by
dedicated gastrointestinal (GI) radiologists with a special
interest in colorectal cancer.
Specimen sections were used to determine the patho-
logic response to therapy by quantifying the tumor
regression grade (TRG) as validated previously.11,17 Tumor
regression was quantified by the relative amount of fibrosis
compared with residual viable tumor, ranging from no
response to no evidence of viable tumor remaining.11 Each
individual grade was defined as follows: grade 0 (no
regression), grade 1 (minor regression:\25% of fibrosis in
the tumor mass), grade 2 (moderate regression: 26–50%
fibrosis within the tumor mass), grade 3 (good regression:
dominant feature of fibrosis [ 50% fibrosis vs the tumor
mass]), grade 4 (complete regression: no evidence of viable
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tumor mass).11 Patients were dichotomized as having a
good response (TRG 3 and 4) or a poor or no response
(TRG 0, 1, and 2).
Statistical Analysis
Statistical evaluation was performed in SPSS (version
22.0; IBM SPSS Statistics, IBM Corp., Armonk, NY, USA).
Grouping of the variables was performed using standard
clinical thresholds. Comparisons between groups of patients
were performed using contingency table analysis (Chi
square) as appropriate, and Fisher’s exact test was used for
those with n less than 5. Logistic regression was performed to
determine univariate relationships between preoperative
clinical predictors and response to nCRT. Multivariate
logistic regression analysis, including all statistically sig-
nificant covariates at a P value of 0.05 or lower, was
performed by a stepwise backward procedure to derive a final
model of the variables that had a statistically significant
relationship between pathologic response and nCRT.
RESULTS
Clinicopathologic Characteristics
The study identified 176 patients who underwent nCRT
and surgical resection for rectal cancer in the period
1999–2010. Patients not suitable for long-course
chemoradiotherapy (n = 66), those who did not complete
the course of chemoradiotherapy (n = 4), those who had
no pretreatment blood results available (n = 10), and those
who had no postoperative histopathology samples available
(n = 17) were excluded from the study, leaving 79 patients
included for the analysis.
The majority of the patients were male (n = 56, 70.1%),
and the median age of the studied cohort was 65 years
(range 39–84 years). At initial presentation and radiologic
examination, the majority of the patients had T3 disease
(n = 50, 63.3%), 74.7% (n = 59) were node-negative, and
7.6% (n = 6) had evidence of metastatic disease. During
the neoadjuvant treatment course, 37 of the patients
(46.8%) were radiologically downstaged, 38% had no stage
change, and 15% (n = 12) progressed radiologically
(Table 1). Using the Ro¨del classification, tumors were
classified as 0 (0%), 1 (22%), 2 (34%), 3 (41%), or 4 (4%)
and thus dichotomized as poor or having no response
(n = 44, 55.7%) or as having a good response (n = 35,
44.3%). At the final pathologic staging, 3 patients (3.8%)
had a complete pathologic response (pT0), 4 patients
(5.1%) were stage pT1, 13 patients (16.5%) were stage
pT2, 47 patients (59.5%) were stage pT3, and 12 patients
(15.2%) were stage pT4 (Table 2).
The majority of the patients had a normal CRP (n = 43,
54.4%), a normal albumin (n = 64, 81%), an mGPS of 0
(n = 43, 54.4%), normal hemoglobin (n = 45, 57%),
normal CEA (n = 32, 45%), an NLR of 5 or lower
(n = 65, 82%), dNLR (n = 41, 52%), an NPS of 0
(n = 56, 71%), and a PLR of 300 or lower (n = 63, 80%)
(Table 2).
Relationships Between Pretreatment Clinicopathologic
Factors and Pathologic Response to Treatment
Pathologic response to CRT was significantly associated
with pathologic T-stage (P\ 0.001), TNM stage
(P = 0.004), vascular invasion (P\ 0.001), perineural
invasion (P = 0.045), and radiologic response (P = 0.003)
(Table 2). Nodal metastases (P = 0.189), CEA
(P = 0.152), and type of chemotherapy (P = 0.875) were
not associated with pathologic response to treatment
(Table 2).
A good pathologic response to treatment was signifi-
cantly associated with an mGPS of 0 (P = 0.022), a
normal NLR (P = 0.052), and a PLR approaching signif-
icance (P = 0.071) (Table 2). There was no association
between pathologic response to treatment and anemia
(P = 0.321), dNLR (P = 0.705), or NPS (P = 0.928)
(Table 2).
A logistic regression model using prognostic preopera-
tive factors identified a high mGPS (odds ratio [OR] 0.27;
95% confidence interval [CI] 0.07–0.96; P = 0.043) and a
poor radiologic response (OR 0.43; 95% CI 0.18–0.99;
P = 0.048) as strong independent predictors of pathologic
response to treatment (Table 3). In the univariate analysis,
NLR (OR 0.27; 95% CI 0.08–0.98; P = 0.046) was asso-
ciated with a pathologic response, but not in the
multivariate analysis (Table 3). As shown in Table 3, PLR
(P = 0.057), dNLR (P = 0.332), and NPS (P = 0.533)
were not associated with a pathologic response to treat-
ment. The preoperative logistic regression model was
further tested with patients who had nonmetastatic disease
only (n = 75). The findings showed that mGPS (hazard
ratio [HR] 0.25; 95% CI 0.07–0.92; P = 0.036) but not
radiologic response (HR 0.48; 95% CI 0.20–1.13;
P = 0.094) remained an independent predictor of response
to nCRT.
We next created a logistic regression model to test the
predictive value of mGPS in the context of prognostic
postoperative variables including vascular invasion, per-
ineural invasion, and TNM staging (Table 4). We found
that mGPS (OR 0.16; 95% CI 0.04–0.73; P = 0.018)
remained a strong independent predictor of pathologic
response, together with vascular invasion (OR 0.28; 95%
CI 0.09–0.84; P = 0.023). Radiologic response (OR 0.59;
95% CI 0.22–1.62; P = 0.305) was not found to be
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significant in the model containing pre- and postoperative
prognostic clinicopathologic variables.
DISCUSSION
The study showed an association between a systemic
inflammatory response and a poor response to nCRT as
determined by the Ro¨del tumor regression grade for
patients undergoing surgery for rectal cancer. This is the
first study to assess SIR comprehensively using a variety of
prognostic markers of systemic inflammation and its
association with response to neoadjuvant therapy in rectal
cancer. The findings demonstrated that mGPS is indepen-
dently associated with response to treatment and may offer
further insight into the interaction between the host
immune response and tumor regression.18,19 Our study
further demonstrated that response to nCRT, assessed
pathologically, is variable (good response of only 44%) and
associated with adverse markers of long-term outcome
including TNM stage, vascular invasion, and perineural
invasion (Tables 1, 2).
Tumor regression grade offers a clinically useful
parameter for determining variable rates of response to
neoadjuvant therapy. Several scoring systems have been
proposed based on the ratio of fibrosis and residual tumor
cells, with fairly similar categorical determinants.11,20,21
These scoring systems predict improved disease-free and
cancer-specific survival, but it remains to be determined
which is best. The main advantage of this method is that it
requires no additional laboratory testing or time and has
good interobserver concordance. However, it has limita-
tions. Semi-quantitative at best, it is based on selected areas
of the tumor and may not fully account for intra-tumoral
heterogeneity. Yet, allowing for its limitations, quantifying
TABLE 1 Clinicopathologic characteristics of patients undergoing
neoadjuvant chemoradiotherapy (nCRT) and surgery for rectal cancer
Factors Patients
(n = 79)
n (%)
Sex
Female 23 (29)
Male 56 (71)
Age (years)
\65 36 (46)
65–74 34 (43)
[75 9 (11)
T-stage
0 (complete pathologic response) 3 (4)
1 4 (5)
2 13 (16)
3 47 (60)
4 12 (15)
N-stage
0 50 (63)
1 14 (18)
2 15 (19)
M-stage
0 75 (95)
1 4 (5)
TNM stage
0 3 (4)
1 13 (16)
2 33 (42)
3 26 (33)
4 4 (5)
Differentiation
Moderately/well 68 (86)
Poor 10 (13)
Unknown 1 (1)
Vascular invasion
No 48 (61)
Yes 30 (38)
Unknown 1 (1)
Perineural invasion
No 67 (85)
Yes 9 (11)
Unknown 3 (4)
Resection margin
Not involved 65 (82)
Involved 14 (18)
Neoadjuvant chemotherapy regimen
Capecitabine 27 (34)
5-FU 44 (56)
Other 8 (10)
Surgical procedure
TABLE 1 continued
Factors Patients
(n = 79)
n (%)
Anterior resection 38 (48)
Abdominoperineal resection 30 (38)
Hartmann’s resection 2 (3)
Unknown 9 (11)
Radiologic response
Good response 37 (47)
No response 30 (38)
Disease progression 12 (15)
Pathologic response
No response 44 (56)
Good response 35 (44)
TNM tumor-node-metastasis, 5-FU 5-fluorouracil
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TABLE 2 Association between clinicopathologic factors and pathologic response to neoadjuvant chemoradiotherapy (nCRT)
Clinicopathologic factors No response patients (n = 44)
n (%)
Good response patients (n = 35)
n (%)
P value
Sex
Female 15 (34) 8 (23) 0.275
Male 29 (66) 27 (77)
Age (years)
\65 16 (36) 20 (57) 0.127
65–74 21 (48) 13 (37)
[75 7 (16) 2 (6)
T-stage
0 (complete pathologic response) 0 (0) 3 (9) \0.001a
1 0 (0) 4 (11)
2 3 (7) 10 (29)
3 31 (70) 16 (46)
4 10 (23) 2 (6)
N-stage
0 24 (54) 26 (74) 0.189
1 10 (23) 4 (11)
2 10 (23) 5 (14)
M-stage
0 41 (93) 34 (97) 0.399a
1 3 (7) 1 (3)
TNM stage
0 0 (0) 3 (0) 0.004
1 2 (4) 11 (31)
2 22 (50) 11 (31)
3 17 (39) 9 (26)
4 3 (7) 1 (3)
Differentiation
Moderately/well 38 (86) 30 (88) 0.543a
Poor 6 (14) 4 (12)
Vascular invasion
No 19 (43) 29 (85) \0.001
Yes 25(57) 5 (15)
Perineural invasion
No 36 (82) 31 (97) 0.045a
Yes 8 (18) 1 (3)
Resection margin
Not involved 34 (77) 31 (89) 0.156a
Involved 10 (23) 4 (11)
Neoadjuvant chemotherapy regimen
Capecitabine 16 (36) 11 (31) 0.875
5-FU 24 (55) 20 (57)
Other 4 (9) 4 (11)
Surgical procedure
Anterior resection 21 (48) 17 (49) 0.911
Abdominoperineal resection 16 (36) 14 (40)
Hartmann’s resection 1 (2) 1 (3)
Unknown 6 (14) 3 (9)
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the ratio of fibrosis to residual cancer tissue is the best
method we currently have for predicting response to
neoadjuvant therapy. However, this can only be used ret-
rospectively after nCRT and thus cannot be used as a
predictive biomarker before surgery.
Whereas findings have shown that pathologic response
to nCRT, as measured by TRG, predicts recurrence and
survival, the value of post-nCRT MRI remains controver-
sial.22 Some studies have previously suggested poor
correlation between posttreatment MRI appearances and
clinical outcome.22–24 However, prospectively controlled
studies have suggested that tumor regression can be accu-
rately determined using post-nCRT MRI.25 A radiologic
MRI assessment of tumor regression, as measured by the
degree of fibrosis replacing pretreatment tumor, has been
shown to correlate with both DFS survival and overall
survival for patients with rectal cancer.25
Recently, MRI volumetry has allowed more accurate
assessment of tumor size than traditional uni-dimensional
measurements.23 Reports show that MRI volumetry is an
accurate predictor of pathologic response to treatment for
patients who receive neoadjuvant therapy for rectal can-
cer.23,26,27 However, the reported studies contained small
numbers and did not report correlation with overall sur-
vival and DFS.23,26,27 We observed strong associations
between radiologic downstaging and pathologic response
to nCRT, and thus radiologic response can be a useful
adjunct in treatment decisions after nCRT.
In the absence of acute illness, what drives systemic
inflammation is poorly understood, but chronic disease,
TABLE 2 continued
Clinicopathologic factors No response patients (n = 44)
n (%)
Good response patients (n = 35)
n (%)
P value
Radiologic response
Disease progression 9 (21) 3 (8) 0.003
No change 22 (50) 8 (23)
Good response 13 (29) 24 (69)
mGPS
0 21 (55) 22 (88) 0.022
1 9 (24) 1 (4)
2 8 (21) 2 (8)
Hemoglobin
Normal ([13 g/dL [men];[11.5 g/dL [women]) 23 (53) 22 (65) 0.321
Anemia (\13 g/dL [men];\11.5 g/dL [women]) 20 (47) 12 (35)
CEA
Normal (B5 lg/L) 14 (43) 18 (62) 0.152
High ([5 lg/L) 18 (56) 11 (38)
NLR
Normal (B5) 33 (75) 32 (91) 0.052a
High ([5) 11 (25) 3 (9)
dNLR
Normal (\2) 22 (50) 19 (54) 0.705
High (C2) 22 (50) 16 (46)
NPS
0 31 (70) 25 (71) 0.928
1 10 (23) 7 (20)
2 3 (7) 3 (9)
PLR
Normal (B300) 32 (73) 31 (89) 0.071a
High ([300) 12 (27) 4 (11)
TNM tumor-node-metastasis, 5-FU 5-fluorouracil, mGPS modified Glasgow prognostic score, CEA carcinoembryonic antigen, NLR neutrophil
lympocyte ratio, dNLR derived neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio
a Fisher’s exact test
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deprivation, and lifestyle changes have been impli-
cated.28–30 It is likely, however, that in colorectal cancer,
systemic inflammation is a response to the tumor and the
tumor microenvironment itself. The pro-inflammatory
cytokine interleukin-6 (IL-6), appears to play a key role in
both local and systemic inflammation in colorectal cancer,
with an association between IL-6 expression and more
pronounced systemic inflammation (as measured by
mGPS) in operable colorectal cancer.31,32 It has been
proposed that elevated serum IL-6 is associated with tumor
necrosis, angiogenesis, disease progression, and
metastasis.31
An elevated CRP has been associated with poor out-
come after neoadjuvant therapy and surgery for rectal
cancer.14,33 Kim et al.33 observed that CRP expression was
significantly higher in nonresponders than in responders,
consistent with our findings. We also demonstrated in the
univariate analysis that NLR, but not PLR, was associated
with response to therapy (Table 3). The prognostic value of
NLR and PLR have been validated, and previous studies
have demonstrated that both are associated with long-term
outcomes for patients undergoing nCRT in rectal can-
cer.10,34 We did not find any correlation between dNLR
and NPS with response to treatment, which recently has
been claimed to be predictive of long-term outcomes in
colorectal cancer.15,16
This study demonstrated that a pretreatment mGPS
score of 0 was independently prognostic of a pathologic
response to chemoradiotherapy, even when analyzed in a
model with prognostic postoperative variables such as
TNM stage, vascular invasion, and perineural invasion
(Tables 3, 4). Radiologic response assessed after treatment
also was closely correlated with a good pathologic
response and independently prognostic of such a response
in the preoperative regression model (Table 3). This sug-
gests that these preoperative measures can be used to assist
TABLE 3 Comparison between preoperative clinical factors and good pathologic response to neoadjuvant chemoradiotherapy (nCRT)
Univariate analysis P value Multivariate analysis P value
OR (95% CI)a OR (95% CI)a
mGPS (0 vs 1/2) 0.18 (0.05–0.60) 0.006 0.27 (0.07–0.96) 0.043
NLR (normal/high) 0.27 (0.08–0.98) 0.046 0.72 (0.17–3.04) 0.658
PLR (normal vs high) 0.33 (0.11–1.03) 0.057
dNLR (normal vs high) 0.73 (0.38–1.39) 0.332
NPS (normal vs high) 0.77 (0.34–1.75) 0.533
Radiologic response (good response vs rest) 0.36 (0.18–0.71) 0.003 0.43 (0.18–0.99) 0.048
OR odds ratio, CI confidence interval, mGPS modified Glasgow prognostic score, NLR neutrophil lympocyte ratio, PLR platelet-to-lymphocyte
ratio, dNLR derived neutrophil-to-lymphocyte ratio, NPS neutrophil-platelet score
a Odds ratios and 95% confidence intervals are generated from the logistic regression model
TABLE 4 Comparison between pre- and postoperative clinicopathologic factors and a good pathologic response to neoadjuvant chemora-
diotherapy (nCRT)
Univariate analysis P value Multivariate analysis P value
OR (95% CI)a OR (95% CI)a
mGPS (0 vs 1/2) 0.18 (0.05–0.60) 0.006 0.16 (0.04–0.73) 0.018
NLR (normal/high) 0.27 (0.08–0.98) 0.046 0.98 (0.22–4.39) 0.976
PLR (normal vs high) 0.33 (0.11–1.03) 0.057
dNLR (normal vs high) 0.73 (0.38–1.39) 0.332
NPS (normal vs high) 0.77 (0.34–1.75) 0.533
Radiologic response (good response vs rest) 0.36 (0.18–0.71) 0.003 0.59 (0.22–1.62) 0.305
Vascular invasion 0.20 (0.08–0.52) 0.001 0.28 (0.09–0.84) 0.023
Perineural invasion 0.13 (0.02–1.00) 0.050 0.62 (0.05–7.67) 0.713
TNM stage (1/2 vs 3/4) 0.50 (0.23–1.07) 0.074
Margin involvement 0.40 (0.13–1.28) 0.121
Peritoneal invasion 0.25 (0.05–1.18) 0.080
OR odds ratio, CI confidence interval, mGPS modified Glasgow prognostic score, NLR neutrophil lympocyte ratio, PLR platelet-to-lymphocyte
ratio, dNLR derived neutrophil-to-lymphocyte ratio, NPS neutrophil-platelet score, TNM tumor-node-metastasis
a Odds ratios and 95% confidence intervals are generated from the logistic regression model
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in clinical decision making before surgeons proceed with
surgery because pathologic response can be assessed only
postoperatively. Interdependent postoperative prognostic
pathologic variables such as TNM stage, vascular invasion,
and perineural invasion are dependent on the pathologic
response to nCRT. Thus, measures of SIR were tested in
regression models using both pre- and postoperatively
available variables to determine its prognostic utility in the
pretreatment setting.
Several proposed biomarkers are reported to predict
response to neoadjuvant therapy in rectal cancer, yet none
have entered routine practice because of problems with
methodology and validation.35 Serum CRP and albumin,
however, are widely used as markers of systemic inflam-
mation. The mGPS is validated as a marker of systemic
inflammation and correlates with long-term survival after
resection for colorectal carcinoma.1
This study was limited by a sample size slightly smaller
than those in other published studies of this type.10,33 This
reflects the difficulties of studying a small subtype of
patients with colorectal cancer. However, our cohort had
comprehensive assessment of the pretreatment systemic
inflammatory response, which had not been performed in
previous studies. Furthermore, only patients who com-
pleted long-course chemoradiotherapy were included in the
study because findings have previously shown this to be
superior to short-course radiotherapy alone.36
Our study did not aim to determine long-term survival
and its association with SIR and response to neoadjuvant
CRT in this patient cohort. Determinants of survival after
resection for rectal cancer are multiple, including postop-
erative complications, adjuvant therapy, and surgical
factors. Thus, our study focused on markers of response to
treatment, which have previously been validated as pre-
dictors of long-term outcome.11,17
In conclusion, the current study demonstrated for the
first time an association between the presence of a SIR and
poor pathologic response to nCRT in patients with rectal
cancer. We propose that our study results be validated in an
independent cohort with strict follow-up data collection to
assess this relationship with long-term survival. The role of
anti-inflammatory or immune modulatory therapies in this
setting requires further investigation to improve response
to nCRT among patients with rectal cancer.
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